Indication: Non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.

Indication: Non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.

Indication: 1. Various types of acute and chronic hepatitis. 2. Malignant tumors. 3. Other diseases caused by low immune function (such as repeated colds, recurrent oral ulcers, skin diseases, condyloma acuminatum, etc.). 4. Can significantly reduce or eliminate the side effects of hair loss and vomiting caused by radiotherapy and chemotherapy.

Indication: Used to treat leukemia, malignant lymphoma, multiple myeloma, breast cancer, lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, ovarian cancer, etc.

Indication: Acute leukemia and malignant lymphoma, breast cancer, bronchial lung cancer, ovarian cancer, Wilms tumor, soft tissue sarcoma, bladder cancer, testicular cancer, prostate cancer, gastric cancer, liver cancer (including primary hepatocellular carcinoma and metastatic cancer) and medullary thyroid cancer and other solid tumors.

Indication: Acute leukemia and malignant lymphoma, breast cancer, bronchial lung cancer, ovarian cancer, Wilms tumor, soft tissue sarcoma, bladder cancer, testicular cancer, prostate cancer, gastric cancer, liver cancer (including primary hepatocellular carcinoma and metastatic cancer) and medullary thyroid cancer and other solid tumors.

Indication: It is the first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is the first-line treatment for SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is the commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. PVB (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers, with a remission rate of 50℅ to 80℅. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: It has a wide anti-tumor spectrum and is clinically used to treat testicular malignant tumors. It has good effects on embryonal tumors and seminoma, and has no cross-resistance with commonly used drugs. It has good effects on ovarian cancer, breast cancer and bladder cancer. It also has certain effects on head and neck cancer, lung cancer, esophageal cancer, malignant melanoma, malignant lymphoma, soft tissue sarcoma and cancerous pleural effusion and ascites. It has good effects when used in combination with other anticancer drugs.

Indication: This product is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: Used for various sarcomas such as nasopharyngeal carcinoma, ovarian cancer, bladder cancer, testicular cancer, lymphosarcoma, reticular cell sarcoma, etc.